CC-90001
- Generic Name
- CC-90001
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C16H27N5O2
- CAS Number
- 1403859-14-2
- Unique Ingredient Identifier
- JD5ZWE631K
- Associated Conditions
- -
- Associated Therapies
- -
Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2019-08-07
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 56
- Registration Number
- NCT04048876
- Locations
- 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Digestive Disease Associates, PA, Catonsville, Maryland, United States
A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2020-05-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 60
- Registration Number
- NCT03958864
- Locations
- 🇺🇸
Paraxel International, Glendale, California, United States
A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Celgene
- Target Recruit Count
- 40
- Registration Number
- NCT03742882
- Locations
- 🇺🇸
Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville, Knoxville, Tennessee, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸The Texas Liver Institute, San Antonio, Texas, United States
A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 56
- Registration Number
- NCT03363815
- Locations
- 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States
A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 138
- Registration Number
- NCT03142191
- Locations
- 🇺🇸
Local Institution - 502, Dallas, Texas, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis
- First Posted Date
- 2015-07-29
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 16
- Registration Number
- NCT02510937
- Locations
- 🇺🇸
LaPorte County Institute for Clinical Research, Inc, Michigan City, Indiana, United States
🇺🇸Tampa General Hospital, Tampa, Florida, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 26
- Registration Number
- NCT02321644
- Locations
- 🇺🇸
Covance-Daytona Beach, Daytona Beach, Florida, United States
🇺🇸TKL Research, Fair Lawn, New Jersey, United States
First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001
- First Posted Date
- 2014-04-10
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 96
- Registration Number
- NCT02110420
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.